101 
Avexa licenses one of its HIV integrase programs to Chinese partner
Avexa Limited has today announced that it has entered into a license agreement with the Shanghai Institute of Organic Chemistry (SIOC) to develop one of Avexa’s HIV integrase inhibitor series. Under the terms and conditions of the license SIOC will be responsible for all future development costs for the program in China … Read all
|
Anteo Diagnostics signs a deal with Merck
The Board of Anteo announced that it has agreed on the terms of a “Non-Exclusive Supply Agreement” with Merck Chimie SAS (“Merck”), part of the AUD$11.2 billion Merck Group which has operations in 64 countries. The formal agreement expected to be signed this week. This signifies another step toward the success… Read all
|
Avexa new interim CEO appointed
Drug development company Avexa Ltd has appointed drug inventor Dr Jonathan Coates as its new interim chief executive officer. Dr Coates will serve as CEO while the company investigates its commercial options and awaits the outcome of an independent review of its programs. He will also resume his previous role as Avexa's … Read all |
Anteo Diagnostics in Trading halt
Anteo Diagnostics is in trading halt pending the announcement of a non-exclusive agreement for the supply of one of its products. Expected to begin trading again on the 14th. Read all
|
Avexa general meeting replaces directors
Avexa Ltd said a general meeting held today, requisitioned by a group of shareholders with not less than 5% of Avexa, removed Nathan Drona as a director, appointed Stephen Crowley and Bruce Hewett as directors and removed Uri Ratner who had been appointed a director on May 19. Avexa had asked shareholders to vote… Read all |
Alchemia potential competitor
Alchemia Ltd has become aware of a potential competitor for its fondaparinux sodium, a generic version of GlaxoSmithKline’s Arixtra synthetic anticoagulant used for the prevention of deep vein thrombosis. Apicore LLC has filed a drug master file (DMF) for the fondaparinux sodium active pharmaceutical ingredi… Read all |
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use